Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: A Cancer Journal for Clinicians. 2015;65(1):5–29.

von Verschuer U, Schnell R, Tessen HW, et al. Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer—final results from the prospective German TLK cohort study. Lung Cancer. 2017;112:216–24.

Article  Google Scholar 

Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8.

Article  CAS  PubMed  Google Scholar 

Mok TS, Wu Y‑L, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.

Article  CAS  PubMed  Google Scholar 

Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis. J Clin Pharm Ther. 2013;105(9):595–605.

CAS  Google Scholar 

Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12(3):839.

Article  CAS  PubMed  Google Scholar 

Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497.

Article  ADS  CAS  PubMed  Google Scholar 

Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer. Cancer Res. 2004;64(24):8919.

Article  CAS  PubMed  Google Scholar 

Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.

Article  CAS  PubMed  Google Scholar 

Girard N, Sima CS, Jackman DM, et al. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J. 2012;39(2):366.

Article  CAS  PubMed  Google Scholar 

Rios Velazquez E, Parmar C, Liu Y, et al. Somatic mutations drive distinct imaging phenotypes in lung cancer. Cancer Res. 2017;77(14):3922–30.

Article  CAS  PubMed  Google Scholar 

Loughran CF, Keeling CR. Seeding of tumour cells following breast biopsy: a literature review. Br J Radiol. 2011;84(1006):869–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang B, Wang QG, Lu M, et al. Correlations study between (18)F-FDG PET/CT metabolic parameters predicting epidermal growth factor receptor mutation status and prognosis in lung adenocarcinoma. Front Oncol. 2019;9:589.

Article  PubMed  PubMed Central  Google Scholar 

Liu Y, Kim J, Qu F, et al. CT features associated with epidermal growth factor receptor mutation status in patients with lung adenocarcinoma. Radiology. 2016;280(1):271–80.

Article  PubMed  Google Scholar 

Yano M, Sasaki H, Kobayashi Y, et al. Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma. J Thorac Oncol. 2006;1(5):413–6.

Article  PubMed  Google Scholar 

Zhou JY, Zheng J, Yu ZF, et al. Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations. Eur Radiol. 2015;25(5):1257–66.

Article  CAS  PubMed  Google Scholar 

Kim H, Park C, Keam B, Park S, Kim M, Kim T, et al. The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors. PLoS ONE. 2017;12:e187500.

Article  PubMed  PubMed Central  Google Scholar 

Park S, Ha S, Lee S, Paeng J, Keam B, Kim T, et al. Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS ONE. 2018;13:e189766.

Article  PubMed  PubMed Central  Google Scholar 

Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.

Article  ADS  CAS  PubMed  Google Scholar 

Zhou B, Xu J, Tian Y, Yuan S, Li X. Correlation between radiomic features based on contrast-enhanced computed tomography images and Ki-67 proliferation index in lung cancer: A preliminary study. Thora Cancer. 2018;9(10):1235–40.

Article  Google Scholar 

Ozkan E, West A, Dedelow JA, et al. CT gray-level texture analysis as a quantitative imaging biomarker of epidermal growth factor receptor mutation status in adenocarcinoma of the lung. Am J Roentgenol. 2015;205(5):1016–25.

Article  Google Scholar 

Liu Y, Kim J, Balagurunathan Y, et al. Radiomic features are associated with EGFR mutation status in lung adenocarcinomas. Clin Lung Cancer. 2016;17(5):441–448 e446.

Wang S, Shi J, Ye Z, et al. Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning. Eur Respir J. 2019;53(3).

Locatelli-Sanchez M, Couraud S, Arpin D, Riou R, Bringuier P‑P, Souquet P‑J. Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: Exons 18–21 sequencing results of 753 patients and subsequent clinical outcomes. Lung. 2013;191(5):491–9.

Article  CAS  PubMed  Google Scholar 

Cheng N‑M, Fang DY‑H, Tung-Chieh CJ, et al. Textural Features of Pretreatment 18F-FDG PET/CT Images: Prognostic Significance in Patients with Advanced T‑Stage Oropharyngeal Squamous Cell Carcinoma. J Nucl Med. 2013;54:1703–9.

Article  CAS  PubMed  Google Scholar 

Stephen Y, Keisha M, Michalis A, et al. Comparison of Texture Features Derived from Static and Respiratory-Gated PET Images in Non-Small Cell Lung Cancer. Plos One. 2014;9(12:e115510.

Google Scholar 

Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJR. Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging. 2013;40(1):133–40.

Article  PubMed  Google Scholar 

W‑s L, L‑j Z. Pang Q‑s, Yuan Z‑y, Li B, Wang P. Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas. Med Oncol. 2013;31(1:771.

Google Scholar 

Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH. EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med. 2009;24(1):48–54.

Article  PubMed  PubMed Central  Google Scholar 

da Cunha SG, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6(1):49–69.

Article  Google Scholar 

Park S, Ha S, Lee S‑H, et al. Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS ONE. 2018;13(1):e189766–e189766.

Article  PubMed  PubMed Central  Google Scholar